Higher APOA1 mRNA levels in pre-chemotherapy effusions from advanced-stage ovarian cancer patients are observed to be an independent prognostic marker with longer overall survival (Tuft Stavnes et al., 2014). The gene discussed is APOA1; the disease is ovarian cancer.